<p>隨着全球市場展現出韌性，主要指數顯著上漲，受益於地緣政治緊張局勢緩解和油價下跌，投資者情緒轉向積極。這種環境為發現未被髮掘的潛力股提供了肥沃的土壤——那些可能被低估或忽視，但在市場條件改善和樂觀情緒恢復的情況下有潛力蓬勃發展的股票。</p>
<h3>全球十大未被髮掘的潛力股，基本面強勁</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>負債權益比</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>健康評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>精華製藥集團</td>
<td>NA</td>
<td>2.42%</td>
<td>18.34%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>MCH 集團</td>
<td>113.30%</td>
<td>18.83%</td>
<td>72.85%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>汕頭超聲儀器研究所</td>
<td>NA</td>
<td>5.53%</td>
<td>14.23%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>江蘇彩虹重工</td>
<td>25.93%</td>
<td>19.62%</td>
<td>2.58%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>投資之家</td>
<td>18.23%</td>
<td>14.46%</td>
<td>47.47%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>中業達電氣</td>
<td>0.41%</td>
<td>-0.88%</td>
<td>-14.90%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>哈馬特集團</td>
<td>44.59%</td>
<td>3.36%</td>
<td>-28.02%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>廈門金龍汽車集團</td>
<td>124.24%</td>
<td>11.47%</td>
<td>34.64%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>武漢華康世紀清潔科技</td>
<td>54.19%</td>
<td>21.27%</td>
<td>6.99%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Plus 集團控股</td>
<td>12.04%</td>
<td>35.49%</td>
<td>-38.12%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們全球未被髮掘的潛力股強勁基本面的 3136 只股票的完整列表。</p>
<p>以下是我們篩選出的股票精選。</p>
<h2>合肥埃科光電 (SHSE:688610)</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 合肥埃科光電有限公司專注於工業成像、高精度光學和光電設備的設計、開發、製造和營銷，市值為 63.3 億人民幣。</p>
<p><strong>運營：</strong> 埃科光電的收入主要來自工業成像、高精度光學和光電設備。公司的淨利潤率反映了其運營效率和盈利趨勢。</p>
<p>合肥埃科光電作為電子行業的靈活參與者，過去一年盈利增長達 306.8%，遠超行業平均水平 12.5%。該公司報告 2025 年 12 月的銷售額為 4.4031 億人民幣，淨收入為 6409 萬人民幣，反映出強勁的運營表現。儘管近期股價波動較大，合肥埃科的負債權益比在五年內顯著改善，從 51.1% 降至僅 2.6%，顯示出強健的財務健康狀況，為未來在其市場細分中的擴展機會奠定了良好基礎。</p>
<ul>
<li>通過閲讀我們的健康報告，深入瞭解合肥埃科光電的表現。</li>
<li>在我們的歷史部分探索歷史數據，以跟蹤合肥埃科光電的表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8e458cf1-6834-4dd6-81e4-2daca17e774f/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8e458cf1-6834-4dd6-81e4-2daca17e774f/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:688610 截至 2026 年 4 月的盈利和收入增長</p>
<h2>奧美醫療產品有限公司 (SZSE:002950)</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 奧美醫療產品有限公司專注於在中國製造和銷售傷口護理和護理材料產品，市值為 83.9 億人民幣。</p>
<p><strong>運營：</strong> 該公司的收入主要來自傷口護理和護理材料產品的銷售。</p>
<p>奧美醫療產品有限公司展現出引人注目的圖景，過去一年盈利增長達 100.9%，遠超行業的温和增長 1.2%。該公司財務狀況穩健，現金超過總債務，且在五年內將負債權益比從 40.3% 降至 13%。目前交易價格低於公允價值估算的 17.9%，似乎被市場低估。其高質量的盈利和 103.8 倍的利息覆蓋比進一步突顯了財務健康，而積極的自由現金流則表明運營效率良好，且對這家有前景的醫療設備製造商沒有立即的流動性擔憂。</p>
<ul>
<li>在我們的健康報告中更深入地瞭解奧美醫療產品有限公司的潛力。</li>
<li>通過我們的歷史報告獲取奧美醫療產品有限公司的過去趨勢和表現的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/54c50ae0-1fc5-4a90-acdb-e8d67c88fa1e/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/54c50ae0-1fc5-4a90-acdb-e8d67c88fa1e/chart/debt-equity-history-analysis"/></p>
<p>SZSE:002950 截至 2026 年 4 月的負債權益比</p>
<h2>江蘇聚傑微纖科技集團 (SZSE:300819)</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 江蘇聚傑微纖科技集團有限公司專注於微纖維材料及相關產品的生產和銷售，市值為 69.4 億人民幣。</p>
<p><strong>運營：</strong> 該公司的收入主要來自其紡織和服裝業務，產生了 5.652 億人民幣的收入。</p>
<p>聚傑微纖作為紡織行業的靈活參與者，展現出引人注目的財務動態。在過去五年中，其負債權益比從 3% 顯著降低至 1.3%，顯示出更強的資產負債表。該公司去年盈利增長 1.8%，超出奢侈品行業平均水平 1.5%。隨着過去的高質量盈利和截至 2024 年 12 月的 5800 萬美元的正自由現金流，儘管近期股價波動，似乎仍然有進一步穩定的潛力。展望未來，預測顯示年盈利增長率超過 36%，暗示在這一細分市場中存在潛在的價值創造機會。</p>
<ul>
<li>點擊這裏訪問我們的完整健康分析報告，以瞭解江蘇聚傑微纖科技集團的動態。</li>
<li>通過查看我們的歷史表現報告，獲取江蘇聚傑微纖科技集團的歷史表現見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/47f2906c-4229-4566-9f9a-d3c86f517ad7/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/47f2906c-4229-4566-9f9a-d3c86f517ad7/chart/debt-equity-history-analysis"/></p>
<p>截至 2026 年 4 月的 SZSE:300819 債務與股本比率</p>
<h2>讓它發生</h2>
<ul>
<li>解鎖更多寶藏！我們的全球未被發現的強基本面寶藏篩選器為您挖掘了 3133 家更多公司供您探索。點擊這裏揭開我們精心策劃的 3136 家全球未被發現的強基本面寶藏的名單。</li>
<li>這些公司中有哪一些是您資產組合的一部分嗎？利用 Simply Wall St 的投資組合分析能力，全面瞭解它們的表現。</li>
<li>利用 Simply Wall St 的力量進行明智投資，這是您在全球股市中導航的免費指南。</li>
</ul>
<h2>準備好不同的方法了嗎？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>本文由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
<h3><strong>新功能：</strong> 在一個地方管理您的所有股票投資組合</h3>
<p>我們為股票投資者創建了 <strong>終極投資組合伴侶</strong>，<strong>而且是免費的。</strong></p>
<p>• 連接無限數量的投資組合，並以一種貨幣查看您的總額</p>
<p>• 通過電子郵件或手機接收新的警告信號或風險提醒</p>
<p>• 跟蹤您股票的公允價值</p>
<p>免費試用演示投資組合</p>

埃科光電

奧美醫療

聚傑微纖

精華制藥

<p>隨着全球市場展現出韌性並取得顯著收益，投資者情緒轉向積極，為識別被低估的股票創造了機會。報告強調了 10 個未被發現的優質股票，這些公司具有強大的基本面，包括精華製藥集團和合肥埃科光電，它們展現了令人印象深刻的盈利增長和改善的財務健康狀況。像奧美醫療和江蘇聚傑微纖科技集團這樣的公司也表現出強勁的運營業績和未來增長的潛力。整體環境對在股市中發現有前景的投資機會是有利的</p>

<p>As global markets show resilience with notable gains in major indices, buoyed by easing geopolitical tensions and a decline in oil prices, investor sentiment has shifted positively. This environment provides a fertile ground for identifying undiscovered gems—stocks that may be undervalued or overlooked but have the potential to thrive amid improving market conditions and renewed optimism.</p>
<div class="lb-trans"><p>隨着全球市場展現出韌性，主要指數顯著上漲，受益於地緣政治緊張局勢緩解和油價下跌，投資者情緒轉向積極。這種環境為發現未被髮掘的潛力股提供了肥沃的土壤——那些可能被低估或忽視，但在市場條件改善和樂觀情緒恢復的情況下有潛力蓬勃發展的股票。</p>
</div><h3>Top 10 Undiscovered Gems With Strong Fundamentals Globally</h3>
<div class="lb-trans"><h3>全球十大未被髮掘的潛力股，基本面強勁</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Debt To Equity</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Health Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jinghua Pharmaceutical Group</td>
<td>NA</td>
<td>2.42%</td>
<td>18.34%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>MCH Group</td>
<td>113.30%</td>
<td>18.83%</td>
<td>72.85%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shantou Institute of Ultrasonic Instrument</td>
<td>NA</td>
<td>5.53%</td>
<td>14.23%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Jiangsu Rainbow Heavy Industries</td>
<td>25.93%</td>
<td>19.62%</td>
<td>2.58%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>House of Investments</td>
<td>18.23%</td>
<td>14.46%</td>
<td>47.47%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zhongyeda Electric</td>
<td>0.41%</td>
<td>-0.88%</td>
<td>-14.90%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Hamat Group</td>
<td>44.59%</td>
<td>3.36%</td>
<td>-28.02%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Xiamen King Long Motor Group</td>
<td>124.24%</td>
<td>11.47%</td>
<td>34.64%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Wuhan Huakang Century Clean Technology</td>
<td>54.19%</td>
<td>21.27%</td>
<td>6.99%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Plus Group Holdings</td>
<td>12.04%</td>
<td>35.49%</td>
<td>-38.12%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>負債權益比</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>健康評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>精華製藥集團</td>
<td>NA</td>
<td>2.42%</td>
<td>18.34%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>MCH 集團</td>
<td>113.30%</td>
<td>18.83%</td>
<td>72.85%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>汕頭超聲儀器研究所</td>
<td>NA</td>
<td>5.53%</td>
<td>14.23%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>江蘇彩虹重工</td>
<td>25.93%</td>
<td>19.62%</td>
<td>2.58%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>投資之家</td>
<td>18.23%</td>
<td>14.46%</td>
<td>47.47%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>中業達電氣</td>
<td>0.41%</td>
<td>-0.88%</td>
<td>-14.90%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>哈馬特集團</td>
<td>44.59%</td>
<td>3.36%</td>
<td>-28.02%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>廈門金龍汽車集團</td>
<td>124.24%</td>
<td>11.47%</td>
<td>34.64%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>武漢華康世紀清潔科技</td>
<td>54.19%</td>
<td>21.27%</td>
<td>6.99%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Plus 集團控股</td>
<td>12.04%</td>
<td>35.49%</td>
<td>-38.12%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 3136 stocks from our Global Undiscovered Gems With Strong Fundamentals screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們全球未被髮掘的潛力股強勁基本面的 3136 只股票的完整列表。</p>
</div><p>Underneath we present a selection of stocks filtered out by our screen.</p>
<div class="lb-trans"><p>以下是我們篩選出的股票精選。</p>
</div><h2>Hefei I-TEK OptoElectronics (SHSE:688610)</h2>
<div class="lb-trans"><h2>合肥埃科光電 (SHSE:688610)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Hefei I-TEK OptoElectronics Co., Ltd. is engaged in the design, development, manufacturing, and marketing of industrial imaging, high precision optics, and opto-electrical equipment in China with a market cap of CN¥6.33 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 合肥埃科光電有限公司專注於工業成像、高精度光學和光電設備的設計、開發、製造和營銷，市值為 63.3 億人民幣。</p>
</div><p><strong>Operations:</strong> I-TEK OptoElectronics generates revenue primarily from industrial imaging, high precision optics, and opto-electrical equipment. The company's net profit margin reflects its operational efficiency and profitability trends over time.</p>
<div class="lb-trans"><p><strong>運營：</strong> 埃科光電的收入主要來自工業成像、高精度光學和光電設備。公司的淨利潤率反映了其運營效率和盈利趨勢。</p>
</div><p>Hefei I-TEK OptoElectronics, a nimble player in the electronics sector, has demonstrated impressive growth with earnings surging by 306.8% over the past year, outpacing the industry average of 12.5%. The company reported sales of CNY 440.31 million and net income of CNY 64.09 million for the year ending December 2025, reflecting strong operational performance. Despite its volatile share price recently, Hefei I-TEK's debt to equity ratio has significantly improved from 51.1% to just 2.6% over five years, indicating robust financial health and positioning it well for future expansion opportunities in its market segment.</p>
<div class="lb-trans"><p>合肥埃科光電作為電子行業的靈活參與者，過去一年盈利增長達 306.8%，遠超行業平均水平 12.5%。該公司報告 2025 年 12 月的銷售額為 4.4031 億人民幣，淨收入為 6409 萬人民幣，反映出強勁的運營表現。儘管近期股價波動較大，合肥埃科的負債權益比在五年內顯著改善，從 51.1% 降至僅 2.6%，顯示出強健的財務健康狀況，為未來在其市場細分中的擴展機會奠定了良好基礎。</p>
</div><ul>
<li>Get an in-depth perspective on Hefei I-TEK OptoElectronics' performance by reading our health report here.</li>
<li>Explore historical data to track Hefei I-TEK OptoElectronics' performance over time in our Past section.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過閲讀我們的健康報告，深入瞭解合肥埃科光電的表現。</li>
<li>在我們的歷史部分探索歷史數據，以跟蹤合肥埃科光電的表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8e458cf1-6834-4dd6-81e4-2daca17e774f/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/8e458cf1-6834-4dd6-81e4-2daca17e774f/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:688610 Earnings and Revenue Growth as at Apr 2026</p>
<div class="lb-trans"><p>SHSE:688610 截至 2026 年 4 月的盈利和收入增長</p>
</div><h2>Allmed Medical ProductsLtd (SZSE:002950)</h2>
<div class="lb-trans"><h2>奧美醫療產品有限公司 (SZSE:002950)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Allmed Medical Products Co., Ltd specializes in the manufacturing and sale of wound care and nursing material products within China, with a market capitalization of CN¥8.39 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 奧美醫療產品有限公司專注於在中國製造和銷售傷口護理和護理材料產品，市值為 83.9 億人民幣。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from the sale of wound care and nursing material products.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司的收入主要來自傷口護理和護理材料產品的銷售。</p>
</div><p>Allmed Medical Products Ltd. paints an intriguing picture with its impressive earnings growth of 100.9% in the past year, outpacing the industry's modest 1.2%. The company appears financially robust, boasting more cash than total debt and reducing its debt-to-equity ratio from 40.3% to 13% over five years. Trading at a discount of 17.9% below fair value estimates, it seems undervalued by market standards. Its high-quality earnings and strong interest coverage ratio of 103.8x EBIT further highlight financial health, while positive free cash flow indicates operational efficiency without immediate liquidity concerns for this promising player in medical equipment manufacturing.</p>
<div class="lb-trans"><p>奧美醫療產品有限公司展現出引人注目的圖景，過去一年盈利增長達 100.9%，遠超行業的温和增長 1.2%。該公司財務狀況穩健，現金超過總債務，且在五年內將負債權益比從 40.3% 降至 13%。目前交易價格低於公允價值估算的 17.9%，似乎被市場低估。其高質量的盈利和 103.8 倍的利息覆蓋比進一步突顯了財務健康，而積極的自由現金流則表明運營效率良好，且對這家有前景的醫療設備製造商沒有立即的流動性擔憂。</p>
</div><ul>
<li>Take a closer look at Allmed Medical ProductsLtd's potential here in our health report.</li>
<li>Gain insights into Allmed Medical ProductsLtd's past trends and performance with our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的健康報告中更深入地瞭解奧美醫療產品有限公司的潛力。</li>
<li>通過我們的歷史報告獲取奧美醫療產品有限公司的過去趨勢和表現的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/54c50ae0-1fc5-4a90-acdb-e8d67c88fa1e/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/54c50ae0-1fc5-4a90-acdb-e8d67c88fa1e/chart/debt-equity-history-analysis"/></p>
<p>SZSE:002950 Debt to Equity as at Apr 2026</p>
<div class="lb-trans"><p>SZSE:002950 截至 2026 年 4 月的負債權益比</p>
</div><h2>Jiangsu Jujie Microfiber Technology Group (SZSE:300819)</h2>
<div class="lb-trans"><h2>江蘇聚傑微纖科技集團 (SZSE:300819)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Jiangsu Jujie Microfiber Technology Group Co., Ltd. focuses on the production and sale of microfiber materials and related products, with a market cap of CN¥6.94 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 江蘇聚傑微纖科技集團有限公司專注於微纖維材料及相關產品的生產和銷售，市值為 69.4 億人民幣。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its Textile and Clothing Business, which generated CN¥565.20 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司的收入主要來自其紡織和服裝業務，產生了 5.652 億人民幣的收入。</p>
</div><p>Jujie Microfiber, a nimble player in the textile sector, showcases intriguing financial dynamics. Over the past five years, its debt to equity ratio has impressively reduced from 3% to 1.3%, indicating a stronger balance sheet. The company's earnings growth of 1.8% last year outpaced the Luxury industry average of 1.5%. With high-quality past earnings and free cash flow turning positive recently at US$58 million as of December 2024, it seems poised for further stability despite recent share price volatility. Looking ahead, forecasts suggest an annual earnings growth rate of over 36%, hinting at potential value creation opportunities in this niche market segment.</p>
<div class="lb-trans"><p>聚傑微纖作為紡織行業的靈活參與者，展現出引人注目的財務動態。在過去五年中，其負債權益比從 3% 顯著降低至 1.3%，顯示出更強的資產負債表。該公司去年盈利增長 1.8%，超出奢侈品行業平均水平 1.5%。隨着過去的高質量盈利和截至 2024 年 12 月的 5800 萬美元的正自由現金流，儘管近期股價波動，似乎仍然有進一步穩定的潛力。展望未來，預測顯示年盈利增長率超過 36%，暗示在這一細分市場中存在潛在的價值創造機會。</p>
</div><ul>
<li>Click here and access our complete health analysis report to understand the dynamics of Jiangsu Jujie Microfiber Technology Group.</li>
<li>Gain insights into Jiangsu Jujie Microfiber Technology Group's historical performance by reviewing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們的完整健康分析報告，以瞭解江蘇聚傑微纖科技集團的動態。</li>
<li>通過查看我們的歷史表現報告，獲取江蘇聚傑微纖科技集團的歷史表現見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/47f2906c-4229-4566-9f9a-d3c86f517ad7/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/47f2906c-4229-4566-9f9a-d3c86f517ad7/chart/debt-equity-history-analysis"/></p>
<p>SZSE:300819 Debt to Equity as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月的 SZSE:300819 債務與股本比率</p>
</div><h2>Make It Happen</h2>
<div class="lb-trans"><h2>讓它發生</h2>
</div><ul>
<li>Unlock more gems! Our Global Undiscovered Gems With Strong Fundamentals screener has unearthed 3133 more companies for you to explore.Click here to unveil our expertly curated list of 3136 Global Undiscovered Gems With Strong Fundamentals.</li>
<li>Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.</li>
<li>Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖更多寶藏！我們的全球未被發現的強基本面寶藏篩選器為您挖掘了 3133 家更多公司供您探索。點擊這裏揭開我們精心策劃的 3136 家全球未被發現的強基本面寶藏的名單。</li>
<li>這些公司中有哪一些是您資產組合的一部分嗎？利用 Simply Wall St 的投資組合分析能力，全面瞭解它們的表現。</li>
<li>利用 Simply Wall St 的力量進行明智投資，這是您在全球股市中導航的免費指南。</li>
</ul>
</div><h2>Ready For A Different Approach?</h2>
<div class="lb-trans"><h2>準備好不同的方法了嗎？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：</strong> 在一個地方管理您的所有股票投資組合</h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我們為股票投資者創建了 <strong>終極投資組合伴侶</strong>，<strong>而且是免費的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 連接無限數量的投資組合，並以一種貨幣查看您的總額</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通過電子郵件或手機接收新的警告信號或風險提醒</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟蹤您股票的公允價值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免費試用演示投資組合</p>
</div>

在 2026 年 4 月發掘全球尚未被發現的寶石